Biotechnology

The biotechnology sector has been hit particularly hard by the risk-averse sentiment sweeping through global stock markets and after reaching a high in July 2015, the Nasdaq Biotechnology index shed about one-third of its value.

Considering biotech funds

Shift into US equities

Significant progress has been made in the run up to change negotiations in Paris this month, but where are the investment opportunities that will benefit from reducing carbon emissions? Alliance Trust's Mike Appleby explores the implications for investors...

Impact of digital technology and price pressures

Recognise boutiques and passive investing

Fund outperforms index over month

Why has performance suffered this year?

Geoffrey C. Hsu, partner of OrbiMed and manager of the BiotechGrowth trust, assesses the key drivers for the sector in 2016 and beyond.

Focus on high quality companies